References
- Zhang Y, Zhu C, Curado MP, Zheng T, Boyle P. Changing patterns of bladder cancer in the USA: evidence of heterogeneous disease. BJU Int. 2012;109(1):52–56. doi:https://doi.org/10.1111/j.1464-410X.2011.10283.x
- Malats N, Real FX. Epidemiology of bladder cancer. Hematol Oncol Clin North Am. 2015;29(2):177–189. doi:https://doi.org/10.1016/j.hoc.2014.10.001
- Howlader NN, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, et al. Cronin KA SEER Cancer Statistics Review, 1975–2014. Bethesda, MD: National Cancer Institute; 2016.
- Aldousari S, Kassouf W. Update on the management of non-muscle invasive bladder cancer. Can Urol Assoc J. 2010;4(1):56–64. doi:https://doi.org/10.5489/cuaj.777
- Yeung C, Dinh T, Lee J. The health economics of bladder cancer: an updated review of the published literature. Pharmacoeconomics. 2014;32(11):1093–1104. doi:https://doi.org/10.1007/s40273-014-0194-2
- Sylvester RJ. Natural history, recurrence, and progression in superficial bladder cancer. ScientificWorldJournal. 2006;6:2617–2625. doi:https://doi.org/10.1100/tsw.2006.404
- Hidas G, Pode D, Shapiro A, Katz R, Appelbaum L, Pizov G, Zorn KC, Landau EH, Duvdevani M, Gofrit ON, et al. The natural history of secondary muscle-invasive bladder cancer. BMC Urol. 2013;13:23. doi:https://doi.org/10.1186/1471-2490-13-23
- Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, Pruthi R, Quale DZ, Ritch CR, Seigne JD, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol. 2016;196(4):1021–1029. doi:https://doi.org/10.1016/j.juro.2016.06.049
- Chamie K, Litwin MS, Bassett JC, Daskivich TJ, Lai J, Hanley JM, Konety BR, Saigal CS. Recurrence of high-risk bladder cancer: a population-based analysis. Cancer. 2013;119(17):3219–3227. doi:https://doi.org/10.1002/cncr.28147
- Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder. J Urol. 2000;163(4):1124–1129. doi:https://doi.org/10.1016/S0022-5347(05)67707-5
- Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP, Lotan Y, Meeks JJ, Michalski JM, Morgan TM, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline. J Urol. 2017;198(3):552–559. doi:https://doi.org/10.1016/j.juro.2017.04.086
- Milowsky MI, Rumble RB, Booth CM, Gilligan T, Eapen LJ, Hauke RJ, Boumansour P, Lee CT. Guideline on muscle-invasive and metastatic bladder cancer (European Association of Urology Guideline): American society of clinical oncology clinical practice guideline endorsement. J Clin Oncol. 2016;34(16):1945–1952. doi:https://doi.org/10.1200/JCO.2015.65.9797
- Wallerand H, Bernhard J-C, Culine S, Ballanger P, Robert G, Reiter RE, Ferrière J-M, Ravaud A. Targeted therapies in non-muscle-invasive bladder cancer according to the signaling pathways. Urol Oncol. 2011;29(1):4–11. doi:https://doi.org/10.1016/j.urolonc.2009.07.025
- Kiselyov A, Bunimovich-Mendrazitsky S, Startsev V. Key signaling pathways in the muscle-invasive bladder carcinoma: clinical markers for disease modeling and optimized treatment. Int J Cancer. 2016;138(11):2562–2569. doi:https://doi.org/10.1002/ijc.29918
- Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer. 2006;6(3):184–192. doi:https://doi.org/10.1038/nrc1819
- Hosseini A, Ghorbani A. Cancer therapy with phytochemicals: evidence from clinical studies. Avicenna J Phytomed. 2015;5(2):84–97.
- Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol. 2005;17(6):596–603. doi:https://doi.org/10.1016/j.ceb.2005.09.009
- Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 2010;11(5):329–341. doi:https://doi.org/10.1038/nrm2882
- Yu JS, Cui W. Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination. Development. 2016;143(17):3050–3060. doi:https://doi.org/10.1242/dev.137075
- Simonyan L, Renault TT, Novais M. J d C, Sousa MJ, Côrte-Real M, Camougrand N, Gonzalez C, Manon S. Regulation of bax/mitochondria interaction by AKT. FEBS Lett. 2016;590(1):13–21. doi:https://doi.org/10.1002/1873-3468.12030
- Iwenofu OH, Lackman RD, Staddon AP, Goodwin DG, Haupt HM, Brooks JS. Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy. Mod Pathol. 2008;21(3):231–237. doi:https://doi.org/10.1038/modpathol.3800995
- Abdelnour-Berchtold E, Cerantola Y, Roulin D, Dormond-Meuwly A, Demartines N, Dormond O. Rapamycin-mediated FOXO1 inactivation reduces the anticancer efficacy of rapamycin. Anticancer Res. 2010;30(3):799–804.
- Kong D, Yamori T. Advances in development of phosphatidylinositol 3-kinase inhibitors. Curr Med Chem. 2009;16(22):2839–2854. doi:https://doi.org/10.2174/092986709788803222
- Chetram MA, Hinton CV. PTEN regulation of ERK1/2 signaling in cancer. J Recept Signal Transduct Res. 2012;32(4):190–195. doi:https://doi.org/10.3109/10799893.2012.695798
- Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She Q-B, Maurer M, Koujak S, Ferrando AA, Malmström P, Memeo L, et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A. 2007;104(18):7564–7569. doi:https://doi.org/10.1073/pnas.0702507104
- Ching CB, Hansel DE. Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway. Lab Invest. 2010;90(10):1406–1414. doi:https://doi.org/10.1038/labinvest.2010.133
- Platt FM, Hurst CD, Taylor CF, Gregory WM, Harnden P, Knowles MA. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res. 2009;15(19):6008–6017. doi:https://doi.org/10.1158/1078-0432.CCR-09-0898
- López-Knowles E, Hernández S, Malats N, Kogevinas M, Lloreta J, Carrato A, Tardón A, Serra C, Real FX. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res. 2006;66(15):7401–7404. doi:https://doi.org/10.1158/0008-5472.CAN-06-1182
- Seager CM, Puzio-Kuter AM, Patel T, Jain S, Cordon-Cardo C, Mc Kiernan J, Abate-Shen C. Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer. Cancer Prev Res (Phila)). 2009;2(12):1008–1014. doi:https://doi.org/10.1158/1940-6207.CAPR-09-0169
- Wang S, Lu J, You Q, Huang H, Chen Y, Liu K. The mTOR/AP-1/VEGF signaling pathway regulates vascular endothelial cell growth. Oncotarget. 2016;7(33):53269–53276. doi:https://doi.org/10.18632/oncotarget.10756
- Zhang X, Zhang Y. Bladder cancer and genetic mutations. Cell Biochem Biophys. 2015;73(1):65–69. doi:https://doi.org/10.1007/s12013-015-0574-z
- Oka N, Tanimoto S, Taue R, Nakatsuji H, Kishimoto T, Izaki H, Fukumori T, Takahashi M, Nishitani M, Kanayama H-o, et al. Role of phosphatidylinositol-3 kinase/Akt pathway in bladder cancer cell apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand. Cancer Sci. 2006;97(10):1093–1098. doi:https://doi.org/10.1111/j.1349-7006.2006.00294.x
- Shaul YD, Seger R. The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim Biophys Acta. 2007;1773(8):1213–1226. doi:https://doi.org/10.1016/j.bbamcr.2006.10.005
- Kyriakis JM, Avruch J, Mammalian MAPK. Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiol Rev. 2012;92(2):689–737. doi:https://doi.org/10.1152/physrev.00028.2011
- Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16(1):103–119. doi:https://doi.org/10.1517/14728222.2011.645805
- Sui X, Kong N, Ye L, Han W, Zhou J, Zhang Q, He C, Pan H. p38 and JNK MAPK pathways control the balance of apoptosis and autophagy in response to chemotherapeutic agents. Cancer Lett. 2014;344(2):174–179. doi:https://doi.org/10.1016/j.canlet.2013.11.019
- Cuadrado A, Nebreda AR. Mechanisms and functions of p38 MAPK signalling. Biochem J. 2010;429(3):403–417. doi:https://doi.org/10.1042/BJ20100323
- Hernández S, López-Knowles E, Lloreta J, Kogevinas M, Amorós A, Tardón A, Carrato A, Serra C, Malats N, Real FX, et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol. 2006;24(22):3664–3671. doi:https://doi.org/10.1200/JCO.2005.05.1771
- Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF, Knowles MA. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene. 2005;24(33):5218–5225. doi:https://doi.org/10.1038/sj.onc.1208705
- Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004;20:781–810. doi:https://doi.org/10.1146/annurev.cellbio.20.010403.113126
- Komiya Y, Habas R. Wnt signal transduction pathways. Organogenesis. 2008;4(2):68–75. doi:https://doi.org/10.4161/org.4.2.5851
- Zhan T, Rindtorff N, Boutros M. Wnt signaling in cancer. Oncogene. 2017;36(11):1461–1473. doi:https://doi.org/10.1038/onc.2016.304
- Rubinfeld B, Souza B, Albert I, Müller O, Chamberlain SH, Masiarz FR, Munemitsu S, Polakis P. Association of the APC gene product with beta-catenin. Science. 1993;262(5140):1731–1734. doi:https://doi.org/10.1126/science.8259518
- Kastritis E, Murray S, Kyriakou F, Horti M, Tamvakis N, Kavantzas N, Patsouris ES, Noni A, Legaki S, Dimopoulos MA, et al. Somatic mutations of adenomatous polyposis coli gene and nuclear b-catenin accumulation have prognostic significance in invasive urothelial carcinomas: evidence for Wnt pathway implication. Int J Cancer. 2009;124(1):103–108. doi:https://doi.org/10.1002/ijc.23917
- Cancer Genome Atlas Research N. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315–322.
- Urakami S, Shiina H, Enokida H, Kawakami T, Tokizane T, Ogishima T, Tanaka Y, Li L-C, Ribeiro-Filho LA, Terashima M, et al. Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway. Clin Cancer Res. 2006;12(2):383–391. doi:https://doi.org/10.1158/1078-0432.CCR-05-1344
- Ahmad I. The role of WNT signalling in urothelial cell carcinoma. Ann R Coll Surg Engl. 2015;97(7):481–486. doi:https://doi.org/10.1308/rcsann.2015.0008
- Ahmad I, Morton JP, Singh LB, Radulescu SM, Ridgway RA, Patel S, Woodgett J, Winton DJ, Taketo MM, Wu X-R, et al. β-Catenin activation synergizes with PTEN loss to cause bladder cancer formation . Oncogene. 2011;30(2):178–189. doi:https://doi.org/10.1038/onc.2010.399
- Ahmad I, Patel R, Liu Y, Singh LB, Taketo MM, Wu X-R, Leung HY, Sansom OJ. Ras mutation cooperates with β-catenin activation to drive bladder tumourigenesis . Cell Death Dis. 2011;2:e124. doi:https://doi.org/10.1038/cddis.2011.7
- Yuan X, Wu H, Xu H, Xiong H, Chu Q, Yu S, Wu GS, Wu K. Notch signaling: an emerging therapeutic target for cancer treatment. Cancer Lett. 2015;369(1):20–27. doi:https://doi.org/10.1016/j.canlet.2015.07.048
- Hori K, Sen A, Artavanis-Tsakonas S, Notch signaling at a glance. J Cell Sci. 2013;126(Pt 10):2135–2140. doi:https://doi.org/10.1242/jcs.127308
- Rampias T, Vgenopoulou P, Avgeris M, Polyzos A, Stravodimos K, Valavanis C, Scorilas A, Klinakis A. A new tumor suppressor role for the Notch pathway in bladder cancer. Nat Med. 2014;20(10):1199–1205. doi:https://doi.org/10.1038/nm.3678
- Fernandez-Marcos PJ, Serrano M, Maraver A. Bladder cancer and the Notch pathway. Oncotarget. 2015;6(3):1346–1347. doi:https://doi.org/10.18632/oncotarget.3183
- Maraver A, Fernandez-Marcos PJ, Cash TP, Mendez-Pertuz M, Dueñas M, Maietta P, Martinelli P, Muñoz-Martin M, Martínez-Fernández M, Cañamero M, et al. NOTCH pathway inactivation promotes bladder cancer progression. J Clin Invest. 2015;125(2):824–830. doi:https://doi.org/10.1172/JCI78185
- Goriki A, Seiler R, Wyatt AW, Contreras-Sanz A, Bhat A, Matsubara A, Hayashi T, Black PC. Unravelling disparate roles of NOTCH in bladder cancer. Nat Rev Urol. 2018;15(6):345–357. doi:https://doi.org/10.1038/s41585-018-0005-1
- Zhang H, Liu L, Liu C, Pan J, Lu G, Zhou Z, Chen Z, Qian C. Notch3 overexpression enhances progression and chemoresistance of urothelial carcinoma. Oncotarget. 2017;8(21):34362–34373. doi:https://doi.org/10.18632/oncotarget.16156
- Briscoe J, Therond PP. The mechanisms of Hedgehog signalling and its roles in development and disease. Nat Rev Mol Cell Biol. 2013;14(7):416–429. doi:https://doi.org/10.1038/nrm3598
- Shin K, Lee J, Guo N, Kim J, Lim A, Qu L, Mysorekar IU, Beachy PA. Hedgehog/Wnt feedback supports regenerative proliferation of epithelial stem cells in bladder. Nature. 2011;472(7341):110–114. doi:https://doi.org/10.1038/nature09851
- Pignot G, Vieillefond A, Vacher S, Zerbib M, Debre B, Lidereau R, Amsellem-Ouazana D, Bieche I. Hedgehog pathway activation in human transitional cell carcinoma of the bladder. Br J Cancer. 2012;106(6):1177–1186. doi:https://doi.org/10.1038/bjc.2012.55
- Shin K, Lim A, Zhao C, Sahoo D, Pan Y, Spiekerkoetter E, Liao JC, Beachy PA. Hedgehog signaling restrains bladder cancer progression by eliciting stromal production of urothelial differentiation factors. Cancer Cell. 2014;26(4):521–533. doi:https://doi.org/10.1016/j.ccell.2014.09.001
- Saadeldin MK, Shawer H, Mostafa A, Kassem NM, Amleh A, Siam R. New genetic variants of LATS1 detected in urinary bladder and colon cancer. Front Genet. 2014;5:425. doi:https://doi.org/10.3389/fgene.2014.00425
- Zygulska AL, Krzemieniecki K, Pierzchalski P. Hippo pathway - brief overview of its relevance in cancer. J Physiol Pharmacol. 2017;68(3):311–335.
- Shubbar E, Kovács A, Hajizadeh S, Parris TZ, Nemes S, Gunnarsdóttir K, Einbeigi Z, Karlsson P, Helou K. Elevated cyclin B2 expression in invasive breast carcinoma is associated with unfavorable clinical outcome. BMC Cancer. 2013;13(1):1. doi:https://doi.org/10.1186/1471-2407-13-1
- Xia J, Zeng M, Zhu H, Chen X, Weng Z, Li S. Emerging role of Hippo signalling pathway in bladder cancer. J Cell Mol Med. 2018;22(1):4–15. doi:https://doi.org/10.1111/jcmm.13293
- Aaronson DS, Horvath CM. A road map for those who don't know JAK-STAT. Science. 2002;296(5573):1653–1655. doi:https://doi.org/10.1126/science.1071545
- Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci. 2004;117(Pt 8):1281–1283. doi:https://doi.org/10.1242/jcs.00963
- Yang C, Zhang W, Wang L, Kazobinka G, Han X, Li B, Hou T. Musashi-2 promotes migration and invasion in bladder cancer via activation of the JAK2/STAT3 pathway. Lab Invest. 2016;96(9):950–958. doi:https://doi.org/10.1038/labinvest.2016.71
- Itoh M, Murata T, Suzuki T, Shindoh M, Nakajima K, Imai K, Yoshida K. Requirement of STAT3 activation for maximal collagenase-1 (MMP-1) induction by epidermal growth factor and malignant characteristics in T24 bladder cancer cells. Oncogene. 2006;25(8):1195–1204. doi:https://doi.org/10.1038/sj.onc.1209149
- Ho PL, Lay EJ, Jian W, Parra D, Chan KS. Stat3 activation in urothelial stem cells leads to direct progression to invasive bladder cancer. Cancer Res. 2012;72(13):3135–3142. doi:https://doi.org/10.1158/0008-5472.CAN-11-3195
- Massague J. TGFbeta in Cancer. Cell. 2008;134(2):215–230.
- Gupta S, Hau AM, Al-Ahmadie HA, Harwalkar J, Shoskes AC, Elson P, Beach JR, Hussey GS, Schiemann WP, Egelhoff TT, et al. Transforming growth factor-β is an upstream regulator of mammalian target of rapamycin complex 2-dependent bladder cancer cell migration and invasion. Am J Pathol. 2016;186(5):1351–1360. doi:https://doi.org/10.1016/j.ajpath.2016.01.008
- Liang Y, Zhu F, Zhang H, Chen D, Zhang X, Gao Q, Li Y. Conditional ablation of TGF-β signaling inhibits tumor progression and invasion in an induced mouse bladder cancer model . Sci Rep. 2016;6:29479. doi:https://doi.org/10.1038/srep29479
- Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int. 2014;2014:852748. doi:https://doi.org/10.1155/2014/852748
- Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001;37 Suppl 4 (Suppl 4):S3–S8. doi:https://doi.org/10.1016/s0959-8049(01)00230-1
- Carlsson J, Wester K, De La Torre M, Malmstrom PU, Gardmark T. EGFR-expression in primary urinary bladder cancer and corresponding metastases and the relation to HER2-expression. On the possibility to target these receptors with radionuclides. Radiol Oncol. 2015;49(1):50–58. doi:https://doi.org/10.2478/raon-2014-0015
- Bryan RT, Regan HL, Pirrie SJ, Devall AJ, Cheng KK, Zeegers MP, James ND, Knowles MA, Ward DG. Protein shedding in urothelial bladder cancer: prognostic implications of soluble urinary EGFR and EpCAM. Br J Cancer. 2015;112(6):1052–1058. doi:https://doi.org/10.1038/bjc.2015.21
- Sriplakich S, Jahnson S, Karlsson MG. Epidermal growth factor receptor expression: predictive value for the outcome after cystectomy for bladder cancer? BJU Int. 1999;83(4):498–503. doi:https://doi.org/10.1046/j.1464-410x.1999.00914.x
- Nedjadi T, Al-Maghrabi J, Assidi M, Dallol A, Al-Kattabi H, Chaudhary A, Al-Sayyad A, Al-Ammari A, Abuzenadah A, Buhmeida A, et al. Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniques. BMC Cancer. 2016;16:653. doi:https://doi.org/10.1186/s12885-016-2703-5
- Liu X, Zhang W, Geng D, He J, Zhao Y, Yu L. Clinical significance of fibroblast growth factor receptor-3 mutations in bladder cancer: a systematic review and meta-analysis. Genet Mol Res. 2014;13(1):1109–1120. doi:https://doi.org/10.4238/2014.February.20.12
- Simon R, Richter J, Wagner U, Fijan A, Bruderer J, Schmid U, et al. High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Res. 2001;61(11):4514–4519.
- Touat M, Ileana E, Postel-Vinay S, Andre F, Soria JC. Targeting FGFR signaling in cancer. Clin Cancer Res. 2015;21(12):2684–2694. doi:https://doi.org/10.1158/1078-0432.CCR-14-2329
- van Oers JMM, Zwarthoff EC, Rehman I, Azzouzi A-R, Cussenot O, Meuth M, Hamdy FC, Catto JWF. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur Urol. 2009;55(3):650–657. doi:https://doi.org/10.1016/j.eururo.2008.06.013
- di Martino E, Tomlinson DC, Williams SV, Knowles MA. A place for precision medicine in bladder cancer: targeting the FGFRs. Future Oncol. 2016;12(19):2243–2263. doi:https://doi.org/10.2217/fon-2016-0042
- Rebouissou S, Hérault A, Letouzé E, Neuzillet Y, Laplanche A, Ofualuka K, Maillé P, Leroy K, Riou A, Lepage M-L, et al. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma. J Pathol. 2012;227(3):315–324. doi:https://doi.org/10.1002/path.4017
- Yohann Loriot AN, Hoon Park S, García-Donas J, Huddart RA, Burgess EF, Fleming MT, Rezazadeh A, Mellado B, Varlamov S, Joshi M, et al. Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRa): Phase 2 continuous versus intermittent dosing. J Clin Oncol. 2018;36(6_suppl):411. doi:https://doi.org/10.1200/JCO.2018.36.6_suppl.411
- Fus LP, Gornicka B. Role of angiogenesis in urothelial bladder carcinoma. Cent Eur J Urol. 2016;69(3):258–263. doi:https://doi.org/10.5173/ceju.2016.830
- Yang CC, Chu KC, Yeh WM. The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression. Urol Oncol. 2004;22(1):1–6. doi:https://doi.org/10.1016/S1078-1439(03)00015-2
- Kopparapu PK, Boorjian SA, Robinson BD, Downes M, Gudas LJ, Mongan NP, et al. Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer. Anticancer Res. 2013;33(6):2381–2390.
- Mukherjee N, Houston TJ, Cardenas E, Ghosh R. To be an ally or an adversary in bladder cancer: the NF-κB story has not unfolded . Carcinogenesis. 2015;36(3):299–306. doi:https://doi.org/10.1093/carcin/bgu321
- D’Ignazio L, Rocha S. Hypoxia induced NF-kappaB. Cells. 2016;5(1):10. doi:https://doi.org/10.3390/cells5010010
- Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol. 2009;1(6):a001651. doi:https://doi.org/10.1101/cshperspect.a001651
- Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov. 2004;3(1):17–26. doi:https://doi.org/10.1038/nrd1279
- Karashima T, Sweeney P, Kamat A, Huang S, Kim SJ, Bar-Eli M, McConkey DJ, Dinney CPN. Nuclear factor-kappaB mediates angiogenesis and metastasis of human bladder cancer through the regulation of interleukin-8. Clin Cancer Res. 2003;9(7):2786–2797.
- Rodriguez Faba O, Palou-Redorta J, Fernández-Gómez JM, Algaba F, Eiró N, Villavicencio H, Vizoso FJ. Matrix metalloproteinases and bladder cancer: what is new? ISRN Urol. 2012;2012:581539. doi:https://doi.org/10.5402/2012/581539
- Yun SJ, Kim WJ. Role of the epithelial-mesenchymal transition in bladder cancer: from prognosis to therapeutic target. Korean J Urol. 2013;54(10):645–650. doi:https://doi.org/10.4111/kju.2013.54.10.645
- Gerhards S, Jung K, Koenig F, Daniltchenko D, Hauptmann S, Schnorr D, Loening SA. Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma. Urology. 2001;57(4):675–679. doi:https://doi.org/10.1016/s0090-4295(00)01087-6
- Angulo JC, Ferruelo A, Rodriguez-Barbero JM, Nunez C, de Fata FR, Gonzalez J. Detection and molecular staging of bladder cancer using real-time RT-PCR for gelatinases (MMP-2, MMP-9) and TIMP-2 in peripheral blood. Actas Urol Esp. 2011;35(3):127–136. doi:https://doi.org/10.1016/j.acuro.2010.10.006
- Mohammad MA, Ismael NR, Shaarawy SM, El-Merzabani MM. Prognostic value of membrane type 1 and 2 matrix metalloproteinase expression and gelatinase A activity in bladder cancer. Int J Biol Markers. 2010;25(2):69–74. doi:https://doi.org/10.1177/172460081002500202
- Cui X, Shen D, Kong C, Zhang Z, Zeng Y, Lin X, Liu X. NF-κB suppresses apoptosis and promotes bladder cancer cell proliferation by upregulating survivin expression in vitro and in vivo . Sci Rep. 2017;7:40723. doi:https://doi.org/10.1038/srep40723
- Karkoulis PK, Stravopodis DJ, Konstantakou EG, Voutsinas GE. Targeted inhibition of heat shock protein 90 disrupts multiple oncogenic signaling pathways, thus inducing cell cycle arrest and programmed cell death in human urinary bladder cancer cell lines. Cancer Cell Int. 2013;13(1):11. doi:https://doi.org/10.1186/1475-2867-13-11
- Kang S, Kim YB, Kim M-H, Yoon K-S, Kim JW, Park NH, Song YS, Kang D, Yoo K-Y, Kang SB, et al. Polymorphism in the nuclear factor kappa-B binding promoter region of cyclooxygenase-2 is associated with an increased risk of bladder cancer. Cancer Lett. 2005;217(1):11–16. doi:https://doi.org/10.1016/j.canlet.2004.06.053
- Agrawal U, Kumari N, Vasudeva P, Mohanty NK, Saxena S. Overexpression of COX2 indicates poor survival in urothelial bladder cancer. Ann Diagn Pathol. 2018;34:50–55. doi:https://doi.org/10.1016/j.anndiagpath.2018.01.008
- Juan Y-S, Lee Y-L, Long C-Y, Wong J-H, Jang M-Y, Lu J-H, Wu W-J, Huang Y-S, Chang W-C, Chuang S-M, et al. Translocation of NF-κB and expression of cyclooxygenase-2 are enhanced by ketamine-induced ulcerative cystitis in rat bladder . Am J Pathol. 2015;185(8):2269–2285. doi:https://doi.org/10.1016/j.ajpath.2015.04.020
- Aggarwal BB, Sundaram C, Malani N, Ichikawa H. Curcumin: the Indian solid gold. Adv Exp Med Biol. 2007;595:1–75. doi:https://doi.org/10.1007/978-0-387-46401-5_1
- Gupta SC, Sung B, Kim JH, Prasad S, Li S, Aggarwal BB. Multitargeting by turmeric, the golden spice: from kitchen to clinic. Mol Nutr Food Res. 2013;57(9):1510–1528. doi:https://doi.org/10.1002/mnfr.201100741
- Nelson KM, Dahlin JL, Bisson J, Graham J, Pauli GF, Walters MA. The essential medicinal chemistry of curcumin. J Med Chem. 2017;60(5):1620–1637. doi:https://doi.org/10.1021/acs.jmedchem.6b00975
- Ravindran J, Prasad S, Aggarwal BB. Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? Aaps J. 2009;11(3):495–510. doi:https://doi.org/10.1208/s12248-009-9128-x
- Padhye S, Chavan D, Pandey S, Deshpande J, Swamy KV, Sarkar FH. Perspectives on chemopreventive and therapeutic potential of curcumin analogs in medicinal chemistry. Mini Rev Med Chem. 2010;10(5):372–387. doi:https://doi.org/10.2174/138955710791330891
- Hani U, Shivakumar HG. Solubility enhancement and delivery systems of curcumin a herbal medicine: a review. Curr Drug Deliv. 2014;11(6):792–804. doi:https://doi.org/10.2174/1567201811666140825130003
- Gao Y, Shi Q, Xu S, Du C, Liang L, Wu K, Wang K, Wang X, Chang LS, He D, et al. Curcumin promotes KLF5 proteasome degradation through downregulating YAP/TAZ in bladder cancer cells. Int J Mol Sci. 2014;15(9):15173–15187. doi:https://doi.org/10.3390/ijms150915173
- Tian B, Zhao Y, Liang T, Ye X, Li Z, Yan D, Fu Q, Li Y. Curcumin inhibits urothelial tumor development by suppressing IGF2 and IGF2-mediated PI3K/AKT/mTOR signaling pathway. J Drug Target. 2017;25(7):626–636. doi:https://doi.org/10.1080/1061186X.2017.1306535
- Wang J, Wang Z, Wang H, Zhao J, Zhang Z. Curcumin induces apoptosis in EJ bladder cancer cells via modulating C-Myc and PI3K/Akt signaling pathway. World J Oncol. 2011;2(3):113–122. doi:https://doi.org/10.4021/wjon335w
- Zhang L, Yang G, Zhang R, Dong L, Chen H, Bo J, Xue W, Huang Y. Curcumin inhibits cell proliferation and motility via suppression of TROP2 in bladder cancer cells. Int J Oncol. 2018;53(2):515–526. doi:https://doi.org/10.3892/ijo.2018.4423
- Shi J, Zhang X, Shi T, Li H. Antitumor effects of curcumin in human bladder cancer in vitro. Oncol Lett. 2017;14(1):1157–1161. doi:https://doi.org/10.3892/ol.2017.6205
- Liu HS, Ke CS, Cheng HC, Huang CY, Su CL. Curcumin-induced mitotic spindle defect and cell cycle arrest in human bladder cancer cells occurs partly through inhibition of aurora A. Mol Pharmacol. 2011;80(4):638–646. doi:https://doi.org/10.1124/mol.111.072512
- Wang S, Meng Q, Xie Q, Zhang M. Effect and mechanism of resveratrol on drug resistance in human bladder cancer cells. Mol Med Rep. 2017;15(3):1179–1187. doi:https://doi.org/10.3892/mmr.2017.6111
- Liang Z, Lu L, Mao J, Li X, Qian H, Xu W. Curcumin reversed chronic tobacco smoke exposure induced urocystic EMT and acquisition of cancer stem cells properties via Wnt/β-catenin . Cell Death Dis. 2017;8(10):e3066. doi:https://doi.org/10.1038/cddis.2017.452
- Shi J, Wang Y, Jia Z, Gao Y, Zhao C, Yao Y. Curcumin inhibits bladder cancer progression via regulation of β-catenin expression. Tumour Biol. 2017;39(7):1010428317702548. doi:https://doi.org/10.1177/1010428317702548
- Liu Z, Liu J, Zhao L, Geng H, Ma J, Zhang Z, Yu D, Zhong C. Curcumin reverses benzidine-induced epithelial-mesenchymal transition via suppression of ERK5/AP-1 in SV-40 immortalized human urothelial cells. Int J Oncol. 2017;50(4):1321–1329. doi:https://doi.org/10.3892/ijo.2017.3887
- Sun X, Zhang T, Deng Q, Zhou Q, Sun X, Li E, Yu D, Zhong C. Benzidine induces epithelial-mesenchymal transition of human bladder cancer cells through activation of ERK5 pathway. Mol Cells. 2018;41(3):188–197. doi: https://doi.org/10.14348/molcells.2018.2113
- Liang Z, Xie W, Wu R, Geng H, Zhao L, Xie C, Li X, Zhu M, Zhu W, Zhu J, et al. Inhibition of tobacco smoke-induced bladder MAPK activation and epithelial-mesenchymal transition in mice by curcumin. Int J Clin Exp Pathol. 2015;8(5):4503–4513.
- Gandhy SU, Kim K, Larsen L, Rosengren RJ, Safe S. Curcumin and synthetic analogs induce reactive oxygen species and decreases specificity protein (Sp) transcription factors by targeting microRNAs. BMC Cancer. 2012;12:564. doi:https://doi.org/10.1186/1471-2407-12-564
- Chadalapaka G, Jutooru I, Chintharlapalli S, Papineni S, Smith R, Li X, Safe S. Curcumin decreases specificity protein expression in bladder cancer cells. Cancer Res. 2008;68(13):5345–5354. doi:https://doi.org/10.1158/0008-5472.CAN-07-6805
- Chadalapaka G, Jutooru I, Burghardt R, Safe S. Drugs that target specificity proteins downregulate epidermal growth factor receptor in bladder cancer cells. Mol Cancer Res. 2010;8(5):739–750. doi:https://doi.org/10.1158/1541-7786.MCR-09-0493
- Saini S, Arora S, Majid S, Shahryari V, Chen Y, Deng G, Yamamura S, Ueno K, Dahiya R. Curcumin modulates microRNA-203-mediated regulation of the Src-Akt axis in bladder cancer. Cancer Prev Res (Phila)). 2011;4(10):1698–1709. doi:https://doi.org/10.1158/1940-6207.CAPR-11-0267
- Falke J, Parkkinen J, Vaahtera L, Hulsbergen-van de Kaa CA, Oosterwijk E, Witjes JA. Curcumin as treatment for bladder cancer: a preclinical study of cyclodextrin-curcumin complex and BCG as intravesical treatment in an orthotopic bladder cancer rat model. Biomed Res Int. 2018;2018:1–7. doi:https://doi.org/10.1155/2018/9634902
- Kamat AM, Tharakan ST, Sung B, Aggarwal BB. Curcumin potentiates the antitumor effects of Bacillus Calmette-Guerin against bladder cancer through the downregulation of NF-kappaB and upregulation of TRAIL receptors. Cancer Res. 2009;69(23):8958–8966. doi:https://doi.org/10.1158/0008-5472.CAN-09-2045
- Jung EM, Park J-W, Choi KS, Park J-W, Lee HI, Lee K-S, Kwon TK. Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis through CHOP-independent DR5 upregulation. Carcinogenesis. 2006;27(10):2008–2017. doi:https://doi.org/10.1093/carcin/bgl026
- Ledda A, Belcaro G, Dugall M, Luzzi R, Hosoi M, Feragalli B, Cotellese R, Cosentino V, Cosentino M, Eggenhoffner R, et al. A natural pharma standard supplement formulation to control treatment-related toxicity and oxidative stress in genitourinary cancer: a preliminary study. Eur Rev Med Pharmacol Sci. 2017;21(18):4196–4202.
- Park BH, Lim JE, Jeon HG, Seo SI, Lee HM, Choi HY, Jeon SS, Jeong BC. Curcumin potentiates antitumor activity of cisplatin in bladder cancer cell lines via ROS-mediated activation of ERK1/2. Oncotarget. 2016;7(39):63870–6386. doi:https://doi.org/10.18632/oncotarget.11563
- Afsharmoghadam N, Haghighatian Z, Mazdak H, Mirkheshti N, Mehrabi Koushki R, Alavi SA. Concentration- dependent effects of curcumin on 5-fluorouracil efficacy in bladder cancer cells. Asian Pac J Cancer Prev. 2017;18(12):3225–3230. doi:https://doi.org/10.22034/APJCP.2017.18.12.3225
- Wei Y, Pu X, Zhao L. Preclinical studies for the combination of paclitaxel and curcumin in cancer therapy (review). Oncol Rep. 2017;37(6):3159–3166. doi:https://doi.org/10.3892/or.2017.5593
- Shao Y, Zhu W, Da J, Xu M, Wang Y, Zhou J, Wang Z. Bisdemethoxycurcumin in combination with α-PD-L1 antibody boosts immune response against bladder cancer. Onco Targets Ther. 2017;10:2675–2683. doi:https://doi.org/10.2147/OTT.S130653
- Zhang SN, Yong Q, Wu XL, Liu XP. Synergism inhibition of curcumin combined with cisplatin on T24 bladder carcinoma cells and its related mechanism. Zhong Yao Cai. 2014;37(11):2043–2046.
- Burns J, Yokota T, Ashihara H, Lean ME, Crozier A. Plant foods and herbal sources of resveratrol. J Agric Food Chem. 2002;50(11):3337–3340. doi:https://doi.org/10.1021/jf0112973
- Pervaiz S. Resveratrol: from grapevines to mammalian biology. Faseb J. 2003;17(14):1975–1985. doi:https://doi.org/10.1096/fj.03-0168rev
- Gambini J, Inglés M, Olaso G, Lopez-Grueso R, Bonet-Costa V, Gimeno-Mallench L, Mas-Bargues C, Abdelaziz KM, Gomez-Cabrera MC, Vina J, et al. Properties of resveratrol: in vitro and in vivo studies about metabolism, bioavailability, and biological effects in animal models and humans. Oxid Med Cell Longev. 2015;2015:837042. doi:https://doi.org/10.1155/2015/837042
- Penalva R, Morales J, Gonzalez-Navarro CJ, Larraneta E, Quincoces G, Penuelas I, et al. Increased oral bioavailability of resveratrol by its encapsulation in casein nanoparticles. Int J Mol Sci. 2018;19(9):2816. doi:https://doi.org/10.3390/ijms19092816
- Wu M-L, Li H, Yu L-J, Chen X-Y, Kong Q-Y, Song X, Shu X-H, Liu J. Short-term resveratrol exposure causes in vitro and in vivo growth inhibition and apoptosis of bladder cancer cells. PLoS One. 2014;9(2):e89806. doi:https://doi.org/10.1371/journal.pone.0089806
- Bai Y, Mao Q-Q, Qin J, Zheng X-Y, Wang Y-B, Yang K, Shen H-F, Xie L-P. Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo. Cancer Sci. 2010;101(2):488–493. doi:https://doi.org/10.1111/j.1349-7006.2009.01415.x
- Alayev A, Salamon RS, Schwartz NS, Berman AY, Wiener SL, Holz MK. Combination of rapamycin and resveratrol for treatment of bladder cancer. J Cell Physiol. 2017;232(2):436–446. doi:https://doi.org/10.1002/jcp.25443
- Lin X, Wu G, Huo WQ, Zhang Y, Jin FS. Resveratrol induces apoptosis associated with mitochondrial dysfunction in bladder carcinoma cells. Int J Urol. 2012;19(8):757–764. doi:https://doi.org/10.1111/j.1442-2042.2012.03024.x
- Stocco B, Toledo K, Salvador M, Paulo M, Koyama N, Torqueti Toloi MR. Dose-dependent effect of resveratrol on bladder cancer cells: chemoprevention and oxidative stress. Maturitas. 2012;72(1):72–78. doi:https://doi.org/10.1016/j.maturitas.2012.02.004
- Zhou C, Ding J, Wu Y. Resveratrol induces apoptosis of bladder cancer cells via miR‑21 regulation of the Akt/Bcl‑2 signaling pathway . Mol Med Rep. 2014;9(4):1467–1473. doi:https://doi.org/10.3892/mmr.2014.1950
- Bai Y, Yang H, Zhang G, Hu L, Lei Y, Qin Y, Yang Y, Wang Q, Li R, Mao Q, et al. Inhibitory effects of resveratrol on the adhesion, migration and invasion of human bladder cancer cells. Mol Med Rep. 2017;15(2):885–889. doi:https://doi.org/10.3892/mmr.2016.6051
- Yang Y, Li C, Li H, Wu M, Ren C, Zhen Y, Ma X, Diao Y, Ma X, Deng S, et al. Differential sensitivities of bladder cancer cell lines to resveratol are unrelated to its metabolic profile. Oncotarget. 2017;8(25):40289–40304. doi:https://doi.org/10.18632/oncotarget.15041
- Cooper R, Morre DJ, Morre DM. Medicinal benefits of green tea: Part I. Review of noncancer health benefits. J Altern Complement Med. 2005;11(3):521–528. doi:https://doi.org/10.1089/acm.2005.11.521
- Bag A, Bag N. Tea polyphenols and prevention of epigenetic aberrations in cancer. J Nat Sci Biol Med. 2018;9(1):2–5. doi:https://doi.org/10.4103/jnsbm.JNSBM_46_17
- Valcic S, Burr JA, Timmermann BN, Liebler DC. Antioxidant chemistry of green tea catechins. New oxidation products of (-)-epigallocatechin gallate and (-)-epigallocatechin from their reactions with peroxyl radicals. Chem Res Toxicol. 2000;13(9):801–810. doi:https://doi.org/10.1021/tx000080k
- Lambert JD, Lee M-J, Lu H, Meng X, Hong JJJ, Seril DN, Sturgill MG, Yang CS. Epigallocatechin-3-gallate is absorbed but extensively glucuronidated following oral administration to mice. J Nutr. 2003;133(12):4172–4177. doi:https://doi.org/10.1093/jn/133.12.4172
- Mereles D, Hunstein W. Epigallocatechin-3-gallate (EGCG) for clinical trials: more pitfalls than promises? Int J Mol Sci. 2011;12(9):5592–5603. doi:https://doi.org/10.3390/ijms12095592
- Luo KW, Lung WY, Chun X, Luo XL, Huang WR. EGCG inhibited bladder cancer T24 and 5637 cell proliferation and migration via PI3K/AKT pathway. Oncotarget. 2018;9(15):12261–12272. doi:https://doi.org/10.18632/oncotarget.24301
- Feng C, Ho Y, Sun C, Xia G, Ding Q, Gu B. Epigallocatechin gallate inhibits the growth and promotes the apoptosis of bladder cancer cells. Exp Ther Med. 2017;14(4):3513–3518. doi:https://doi.org/10.3892/etm.2017.4981
- Qin J, Xie L-P, Zheng X-Y, Wang Y-B, Bai Y, Shen H-F, Li L-C, Dahiya R. A component of green tea, (-)-epigallocatechin-3-gallate, promotes apoptosis in T24 human bladder cancer cells via modulation of the PI3K/Akt pathway and Bcl-2 family proteins. Biochem Biophys Res Commun. 2007;354(4):852–857. doi:https://doi.org/10.1016/j.bbrc.2007.01.003
- Chen N-G, Lu C-C, Lin Y-H, Shen W-C, Lai C-H, Ho Y-J, Chung J-G, Lin T-H, Lin Y-C, Yang J-S, et al. Proteomic approaches to study epigallocatechin gallate-provoked apoptosis of TSGH-8301 human urinary bladder carcinoma cells: roles of AKT and heat shock protein 27-modulated intrinsic apoptotic pathways. Oncol Rep. 2011;26(4):939–947. doi:https://doi.org/10.3892/or.2011.1377
- Hsieh D-S, Wang H, Tan S-W, Huang Y-H, Tsai C-Y, Yeh M-K, Wu C-J. The treatment of bladder cancer in a mouse model by epigallocatechin-3-gallate-gold nanoparticles. Biomaterials. 2011;32(30):7633–7640. doi:https://doi.org/10.1016/j.biomaterials.2011.06.073
- Rieger-Christ KM, Hanley R, Lodowsky C, Bernier T, Vemulapalli P, Roth M, Kim J, Yee AS, Le SM, Marie PJ, et al. The green tea compound, (-)-epigallocatechin-3-gallate downregulates N-cadherin and suppresses migration of bladder carcinoma cells. J Cell Biochem. 2007;102(2):377–388. doi:https://doi.org/10.1002/jcb.21299
- Jankun J, Keck RW, Selman SH. Epigallocatechin-3-gallate prevents tumor cell implantation/growth in an experimental rat bladder tumor model. Int J Oncol. 2014;44(1):147–152. doi:https://doi.org/10.3892/ijo.2013.2174
- Luo KW, Wei C, Lung WY, Wei XY, Cheng BH, Cai ZM, et al. EGCG inhibited bladder cancer SW780 cell proliferation and migration both in vitro and in vivo via down-regulation of NF-kappaB and MMP-9. J Nutr Biochem. 2017;41:56–64. doi:https://doi.org/10.1016/j.jnutbio.2016.12.004
- Qin J, Wang Y, Bai Y, Yang K, Mao Q, Lin Y, Kong D, Zheng X, Xie L. Epigallocatechin-3-gallate inhibits bladder cancer cell invasion via suppression of pression of NF-κB‑mediated matrix metalloproteinase-9 expression . Mol Med Rep. 2012;6(5):1040–1044. doi:https://doi.org/10.3892/mmr.2012.1054
- Higdon JV, Delage B, Williams DE, Dashwood RH. Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. Pharmacol Res. 2007;55(3):224–236. doi:https://doi.org/10.1016/j.phrs.2007.01.009
- Michaud DS, Spiegelman D, Clinton SK, Rimm EB, Willett WC, Giovannucci EL. Fruit and vegetable intake and incidence of bladder cancer in a male prospective cohort. J Natl Cancer Inst. 1999;91(7):605–613. doi:https://doi.org/10.1093/jnci/91.7.605
- Tang L, Zirpoli GR, Guru K, Moysich KB, Zhang Y, Ambrosone CB, McCann SE. Consumption of raw cruciferous vegetables is inversely associated with bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2008;17(4):938–944. doi:https://doi.org/10.1158/1055-9965.EPI-07-2502
- Abbaoui B, Telu KH, Lucas CR, Thomas-Ahner JM, Schwartz SJ, Clinton SK, Freitas MA, Mortazavi A. The impact of cruciferous vegetable isothiocyanates on histone acetylation and histone phosphorylation in bladder cancer. J Proteomics. 2017;156:94–103. doi:https://doi.org/10.1016/j.jprot.2017.01.013
- Fenwick GH, Mullin WJ. Glucosinolates and their breakdown products in food and food plants. Crit Rev Food Sci Nutr. 1983;18(2):123–201. doi:https://doi.org/10.1080/10408398209527361
- Rouzaud G, Young SA, Duncan AJ. Hydrolysis of glucosinolates to isothiocyanates after ingestion of raw or microwaved cabbage by human volunteers. Cancer Epidemiol Biomarkers Prev. 2004;13(1):125–131. doi:https://doi.org/10.1158/1055-9965.epi-085-3
- Vermeulen M, Klopping-Ketelaars IW, van den Berg R, Vaes WH. Bioavailability and kinetics of sulforaphane in humans after consumption of cooked versus raw broccoli. J Agric Food Chem. 2008;56(22):10505–10509. doi:https://doi.org/10.1021/jf801989e
- Ding Y, Paonessa JD, Randall KL, Argoti D, Chen L, Vouros P, Zhang Y. Sulforaphane inhibits 4-aminobiphenyl-induced DNA damage in bladder cells and tissues. Carcinogenesis. 2010;31(11):1999–2003. doi:https://doi.org/10.1093/carcin/bgq183
- Dinkova-Kostova AT, Fahey JW, Kostov RV, Kensler TW. KEAP1 and done? Targeting the NRF2 pathway with sulforaphane. Trends Food Sci Technol. 2017;69(Pt B):257–269. doi:https://doi.org/10.1016/j.tifs.2017.02.002
- Wang F, Shan Y. Sulforaphane retards the growth of UM-UC-3 xenographs, induces apoptosis, and reduces survivin in athymic mice. Nutr Res. 2012;32(5):374–380. doi:https://doi.org/10.1016/j.nutres.2012.03.014
- Abbaoui B, Riedl KM, Ralston RA, Thomas-Ahner JM, Schwartz SJ, Clinton SK, Mortazavi A. Inhibition of bladder cancer by broccoli isothiocyanates sulforaphane and erucin: characterization, metabolism, and interconversion. Mol Nutr Food Res. 2012;56(11):1675–1687. doi:https://doi.org/10.1002/mnfr.201200276
- Shan Y, Sun C, Zhao X, Wu K, Cassidy A, Bao Y. Effect of sulforaphane on cell growth, G(0)/G(1) phase cell progression and apoptosis in human bladder cancer T24 cells. Int J Oncol. 2006;29(4):883–888. doi:https://doi.org/10.3892/ijo.29.4.883
- Park HS, Han MH, Kim G-Y, Moon S-K, Kim W-J, Hwang HJ, Park KY, Choi YH. Sulforaphane induces reactive oxygen species-mediated mitotic arrest and subsequent apoptosis in human bladder cancer 5637 cells. Food Chem Toxicol. 2014;64:157–165. doi:https://doi.org/10.1016/j.fct.2013.11.034
- Dang Y-M, Huang G, Chen Y-R, Dang Z-F, Chen C, Liu F-L, Guo Y-F, Xie X-D. Sulforaphane inhibits the proliferation of the BIU87 bladder cancer cell line via IGFBP-3 elevation. Asian Pac J Cancer Prev. 2014;15(4):1517–1520. doi:https://doi.org/10.7314/apjcp.2014.15.4.1517
- Jin C-Y, Molagoda IMN, Karunarathne WAHM, Kang S-H, Park C, Kim G-Y, Choi YH. TRAIL attenuates sulforaphane-mediated Nrf2 and sustains ROS generation, leading to apoptosis of TRAIL-resistant human bladder cancer cells. Toxicol Appl Pharmacol. 2018;352:132–141. doi:https://doi.org/10.1016/j.taap.2018.05.022
- Islam SS, Mokhtari RB, Akbari P, Hatina J, Yeger H, Farhat WA. Simultaneous targeting of bladder tumor growth, survival, and epithelial-to-mesenchymal transition with a novel therapeutic combination of acetazolamide (AZ) and sulforaphane (SFN). Target Oncol. 2016;11(2):209–227. doi:https://doi.org/10.1007/s11523-015-0386-5
- Shan Y, Zhang L, Bao Y, Li B, He C, Gao M, Feng X, Xu W, Zhang X, Wang S, et al. Epithelial-mesenchymal transition, a novel target of sulforaphane via COX-2/MMP2, 9/Snail, ZEB1 and miR-200c/ZEB1 pathways in human bladder cancer cells. J Nutr Biochem. 2013;24(6):1062–1069. doi:https://doi.org/10.1016/j.jnutbio.2012.08.004
- Shan Y, Wang X, Wang W, He C, Bao Y. p38 MAPK plays a distinct role in sulforaphane-induced up-regulation of ARE-dependent enzymes and down-regulation of COX-2 in human bladder cancer cells. Oncol Rep. 2010;23(4):1133–1138.
- Shan Y, Wu K, Wang W, Wang S, Lin N, Zhao R, Cassidy A, Bao Y. Sulforaphane down-regulates COX-2 expression by activating p38 and inhibiting NF-kappaB-DNA-binding activity in human bladder T24 cells. Int J Oncol. 2009;34(4):1129–1134. doi:https://doi.org/10.3892/ijo_00000240
- Russo M, Russo GL, Daglia M, Kasi PD, Ravi S, Nabavi SF, Nabavi SM. Understanding genistein in cancer: The "good" and the "bad" effects: A review. Food Chem. 2016;196:589–600. doi:https://doi.org/10.1016/j.foodchem.2015.09.085
- Spagnuolo C, Russo GL, Orhan IE, Habtemariam S, Daglia M, Sureda A, Nabavi SF, Devi KP, Loizzo MR, Tundis R, et al. Genistein and cancer: current status, challenges, and future directions. Adv Nutr. 2015;6(4):408–419. doi:https://doi.org/10.3945/an.114.008052
- Kwon SH, Kang MJ, Huh JS, Ha KW, Lee JR, Lee SK, Lee BS, Han IH, Lee MS, Lee MW, et al. Comparison of oral bioavailability of genistein and genistin in rats. Int J Pharm. 2007;337(1-2):148–154. doi:https://doi.org/10.1016/j.ijpharm.2006.12.046
- Wang Y, Wang H, Zhang W, Shao C, Xu P, Shi CH, Shi JG, Li YM, Fu Q, Xue W, et al. Genistein sensitizes bladder cancer cells to HCPT treatment in vitro and in vivo via ATM/NF-κB/IKK pathway-induced apoptosis. PLoS One. 2013;8(1):e50175. doi:https://doi.org/10.1371/journal.pone.0050175
- Messing E, Gee JR, Saltzstein DR, Kim K, diSant'Agnese A, Kolesar J, Harris L, Faerber A, Havighurst T, Young JM, et al. A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients. Cancer Prev Res (Phila)). 2012;5(4):621–630. doi:https://doi.org/10.1158/1940-6207.CAPR-11-0455
- Shanmugam MK, Shen H, Tang FR, Arfuso F, Rajesh M, Wang L, Kumar AP, Bian J, Goh BC, Bishayee A, et al. Potential role of genipin in cancer therapy. Pharmacol Res. 2018;133:195–200. doi:https://doi.org/10.1016/j.phrs.2018.05.007
- Li Z, Zhang TB, Jia DH, Sun WQ, Wang CL, Gu AZ, et al. Genipin inhibits the growth of human bladder cancer cells via inactivation of PI3K/Akt signaling. Oncol Lett. 2018;15(2):2619–2624.
- Mahgoub E, Kumaraswamy SM, Kader KH, Venkataraman B, Ojha S, Adeghate E, Rajesh M. Genipin attenuates cisplatin-induced nephrotoxicity by counteracting oxidative stress, inflammation, and apoptosis. Biomed Pharmacother. 2017;93:1083–1097. doi:https://doi.org/10.1016/j.biopha.2017.07.018
- Liu H, Dong Y, Gao Y, Du Z, Wang Y, Cheng P, et al. The fascinating effects of baicalein on cancer: a review. Int J Mol Sci. 2016;17(10):1681. doi:https://doi.org/10.3390/ijms17101681
- Wu JY, Tsai KW, Li YZ, Chang YS, Lai YC, Laio YH, et al. Anti-bladder-tumor effect of baicalein from Scutellaria baicalensis Georgi and its application in vivo. Evid Based Complement Alternat Med. 2013;(2013):579751. doi:https://doi.org/10.1155/2013/579751
- Jiang RH, Su WC, Liu HF, Huang HS, Chao JI. Opposite expression of securin and γ-H2AX regulates baicalein-induced cancer cell death . J Cell Biochem. 2010;111(2):274–283. doi:https://doi.org/10.1002/jcb.22697
- Yang Y, Liu K, Yang L, Zhang G. Bladder cancer cell viability inhibition and apoptosis induction by baicalein through targeting the expression of anti-apoptotic genes. Saudi J Biol Sci. 2018;25(7):1478–1482. doi:https://doi.org/10.1016/j.sjbs.2017.03.014
- Choi EP, Hwang HJ, et al. Baicalein induces apoptosis via ROS-dependent activation of caspases in human bladder cancer 5637 cells. Int J Oncology. 2016;49(3):1009–1018. doi:https://doi.org/10.3892/ijo.2016.3606
- Li HZ, Wang Y, et al. Baicalein induces apoptosis via a mitochondrial-dependent caspase activation pathway in T24 bladder cancer cells. Mol Med Rep. 2013;7(1):266–270. doi:https://doi.org/10.3892/mmr.2012.1123
- Jiang L, Song H, Guo H, Wang C, Lu Z. Baicalein inhibits proliferation and migration of bladder cancer cell line T24 by down-regulation of microRNA-106. Biomed Pharmacother. 2018;107:1583–1590. doi:https://doi.org/10.1016/j.biopha.2018.08.107
- Chao JI, Su WC, Liu HF. Baicalein induces cancer cell death and proliferation retardation by the inhibition of CDC2 kinase and survivin associated with opposite role of p38 mitogen-activated protein kinase and AKT. Mol Cancer Ther. 2007;6(11):3039–3048. doi:https://doi.org/10.1158/1535-7163.MCT-07-0281
- Howell AB, Foxman B. Cranberry juice and adhesion of antibiotic-resistant uropathogens. JAMA. 2002;287(23):3082–3083. doi:https://doi.org/10.1001/jama.287.23.3082
- Seeram NP, Adams LS, Hardy ML, Heber D. Total cranberry extract versus its phytochemical constituents: antiproliferative and synergistic effects against human tumor cell lines. J Agric Food Chem. 2004;52(9):2512–2517. doi:https://doi.org/10.1021/jf0352778
- Su Q, Peng M, Zhang Y, Xu W, Darko KO, Tao T, Huang Y, Tao X, Yang X. Quercetin induces bladder cancer cells apoptosis by activation of AMPK signaling pathway. Am J Cancer Res. 2016;6(2):498–508.
- Rockenbach L, Bavaresco L, Fernandes Farias P, Cappellari AR, Barrios CH, Bueno Morrone F, Oliveira Battastini AM. Alterations in the extracellular catabolism of nucleotides are involved in the antiproliferative effect of quercetin in human bladder cancer T24 cells. Urol Oncol. 2013;31(7):1204–1211. doi:https://doi.org/10.1016/j.urolonc.2011.10.009
- Ma L, Feugang JM, Konarski P, Wang J, Lu J, Fu S, Ma B, Tian B, Zou C, Wang Z, et al. Growth inhibitory effects of quercetin on bladder cancer cell. Front Biosci. 2006;11:2275–2285. doi:https://doi.org/10.2741/1970
- Li X, Jiang Q, Wang T, Liu J, Chen D. Comparison of the antioxidant effects of quercitrin and isoquercitrin: understanding the role of the 6''-OH group. Molecules. 2016;21(9):1246. doi:https://doi.org/10.3390/molecules21091246
- Chen F, Chen X, Yang D, Che X, Wang J, Li X, Zhang Z, Wang Q, Zheng W, Wang L, et al. Isoquercitrin inhibits bladder cancer progression in vivo and in vitro by regulating the PI3K/Akt and PKC signaling pathways . Oncol Rep. 2016;36(1):165–172. doi:https://doi.org/10.3892/or.2016.4794
- Wu P, Liu S, Su J, Chen J, Li L, Zhang R, Chen T. Apoptosis triggered by isoquercitrin in bladder cancer cells by activating the AMPK-activated protein kinase pathway. Food Funct. 2017;8(10):3707–3722. doi:https://doi.org/10.1039/c7fo00778g
- Brigelius-Flohe R, Traber MG. Vitamin E: function and metabolism. Faseb J. 1999;13(10):1145–1155.
- Chen F, Li Q, Yu Y, Yang W, Shi F, Qu Y. Association of vitamin C, vitamin D, vitamin E and risk of bladder cancer: a dose-response meta-analysis. Sci Rep. 2015;5:9599. doi:https://doi.org/10.1038/srep09599
- Kanai K, Kikuchi E, Mikami S, Suzuki E, Uchida Y, Kodaira K, Miyajima A, Ohigashi T, Nakashima J, Oya M, et al. Vitamin E succinate induced apoptosis and enhanced chemosensitivity to paclitaxel in human bladder cancer cells in vitro and in vivo. Cancer Sci. 2010;101(1):216–223. doi:https://doi.org/10.1111/j.1349-7006.2009.01362.x
- Ye C, Zhao W, Li M, Zhuang J, Yan X, Lu Q, Chang C, Huang X, Zhou J, Xie B, et al. δ-tocotrienol induces human bladder cancer cell growth arrest, apoptosis and chemosensitization through inhibition of STAT3 pathway . PLoS One. 2015;10(4):e0122712. doi:https://doi.org/10.1371/journal.pone.0122712
- Pareek A, Suthar M, Rathore GS, Bansal V. Feverfew (Tanacetum parthenium L.): A systematic review. Pharmacogn Rev. 2011;5(9):103–110. doi:https://doi.org/10.4103/0973-7847.79105
- Shanmugam R, Kusumanchi P, Appaiah H, Cheng L, Crooks P, Neelakantan S, Peat T, Klaunig J, Matthews W, Nakshatri H, et al. A water soluble parthenolide analog suppresses in vivo tumor growth of two tobacco-associated cancers, lung and bladder cancer, by targeting NF-kappaB and generating reactive oxygen species. Int J Cancer. 2011;128(10):2481–2494. doi:https://doi.org/10.1002/ijc.25587
- Cheng G, Xie L. Parthenolide induces apoptosis and cell cycle arrest of human 5637 bladder cancer cells in vitro. Molecules. 2011;16(8):6758–6768. doi:https://doi.org/10.3390/molecules16086758
- Lv L, Zheng L, Dong D, Xu L, Yin L, Xu Y, Qi Y, Han X, Peng J. Dioscin, a natural steroid saponin, induces apoptosis and DNA damage through reactive oxygen species: a potential new drug for treatment of glioblastoma multiforme. Food Chem Toxicol. 2013;59:657–669. doi:https://doi.org/10.1016/j.fct.2013.07.012
- Zhou Q, Song W, Xiao W. Dioscin induces demethylation of DAPK-1 and RASSF-1alpha genes via the antioxidant capacity, resulting in apoptosis of bladder cancer T24 cells. Excli J. 2017;16:101–112. doi:https://doi.org/10.17179/excli2016-571
- Ho J-N, Byun S-S, Lee S, Oh JJ, Hong SK, Lee SE, Yeon JS. Synergistic antitumor effect of triptolide and cisplatin in cisplatin resistant human bladder cancer cells. J Urol. 2015;193(3):1016–1022. doi:https://doi.org/10.1016/j.juro.2014.09.007
- Yang Y, Zhang LJ, Bai XG, Xu HJ, Jin ZL, Ding M. Synergistic antitumour effects of triptolide plus gemcitabine in bladder cancer. Biomed Pharmacother. 2018;106:1307–1316. doi:https://doi.org/10.1016/j.biopha.2018.07.083
- Chen AY, Chen YC. A review of the dietary flavonoid, kaempferol on human health and cancer chemoprevention. Food Chem. 2013;138(4):2099–2107. doi:https://doi.org/10.1016/j.foodchem.2012.11.139
- Dang Q, Song W, Xu D, Ma Y, Li F, Zeng J, Zhu G, Wang X, Chang LS, He D, et al. Kaempferol suppresses bladder cancer tumor growth by inhibiting cell proliferation and inducing apoptosis. Mol Carcinog. 2015;54(9):831–840. doi:https://doi.org/10.1002/mc.22154
- Qiu W, Lin J, Zhu Y, Zhang J, Zeng L, Su M, Tian Y. Kaempferol modulates DNA methylation and downregulates DNMT3B in bladder cancer. Cell Physiol Biochem. 2017;41(4):1325–1335. doi:https://doi.org/10.1159/000464435
- Wu P, Meng X, Zheng H, Zeng Q, Chen T, Wang W, Zhang X, Su J. Kaempferol attenuates ROS-induced hemolysis and the molecular mechanism of its induction of apoptosis on bladder cancer. Molecules. 2018;23(10):2592. doi:https://doi.org/10.3390/molecules23102592
- Xie F, Su M, Qiu W, Zhang M, Guo Z, Su B, Liu J, Li X, Zhou L. Kaempferol promotes apoptosis in human bladder cancer cells by inducing the tumor suppressor, PTEN. Int J Mol Sci. 2013;14(11):21215–21226. doi:https://doi.org/10.3390/ijms141121215
- Rimando AM, Cuendet M, Desmarchelier C, Mehta RG, Pezzuto JM, Duke SO. Cancer chemopreventive and antioxidant activities of pterostilbene, a naturally occurring analogue of resveratrol. J Agric Food Chem. 2002;50(12):3453–3457. doi:https://doi.org/10.1021/jf0116855
- Chen RJ, Ho CT, Wang YJ. Pterostilbene induces autophagy and apoptosis in sensitive and chemoresistant human bladder cancer cells. Mol Nutr Food Res. 2010;54(12):1819–1832. doi:https://doi.org/10.1002/mnfr.201000067
- Si L, Yang X, Yan X, Wang Y, Zheng Q. Isoliquiritigenin induces apoptosis of human bladder cancer T24 cells via a cyclin-dependent kinase-independent mechanism. Oncol Lett. 2017;14(1):241–249. doi:https://doi.org/10.3892/ol.2017.6159
- Patricia Moreno-Londono A, Bello-Alvarez C, Pedraza-Chaverri J. Isoliquiritigenin pretreatment attenuates cisplatin induced proximal tubular cells (LLC-PK1) death and enhances the toxicity induced by this drug in bladder cancer T24 cell line. Food Chem Toxicol. 2017;109(Pt 1):143–154. doi:https://doi.org/10.1016/j.fct.2017.08.047
- Cheong DHJ, Arfuso F, Sethi G, Wang L, Hui KM, Kumar AP, Tran T. Molecular targets and anti-cancer potential of escin. Cancer Lett. 2018;422:1–8. doi:https://doi.org/10.1016/j.canlet.2018.02.027
- Cheng C-L, Chao W-T, Li Y-H, Ou Y-C, Wang S-S, Chiu K-Y, Yuan S-Y. Escin induces apoptosis in human bladder cancer cells: An in vitro and in vivo study. Eur J Pharmacol. 2018;840:79–88. doi:https://doi.org/10.1016/j.ejphar.2018.09.033
- Fuge O, Vasdev N, Allchorne P, Green JS. Immunotherapy for bladder cancer. Res Rep Urol. 2015;7:65–79. doi:https://doi.org/10.2147/RRU.S63447